NEW YORK (GenomeWeb News) – Applied Proteomics and The ALS Therapy Development Institute (ALS TDI) are collaborating to validate protein biomarkers for tracking the progression of, and developing therapies for, amyotrophic lateral sclerosis, also called Lou Gehrig's disease.

"The absence of viable diagnostic and therapeutic tools for managing and treating ALS is tragic," John Blume, CSO at Applied Proteomics, said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.